Development of a sample pooling strategy for the serodiagnosis of small ruminant lentiviral infections using the ELITEST-MVV ELISA

2007 ◽  
Vol 70 (2-3) ◽  
pp. 194-199 ◽  
Author(s):  
J.M.A. Brinkhof ◽  
D.J. Houwers ◽  
C. van Maanen
Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1166
Author(s):  
Immacolata Polvere ◽  
Elena Silvestri ◽  
Lina Sabatino ◽  
Antonia Giacco ◽  
Stefania Iervolino ◽  
...  

Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, it has been clear that testing large groups of the population was the key to stem infection and prevent the effects of the coronavirus disease of 2019, mostly among sensitive patients. On the other hand, time and cost-sustainability of virus detection by molecular analysis such as reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) may be a major issue if testing is extended to large communities, mainly asymptomatic large communities. In this context, sample-pooling and test grouping could offer an effective solution. Here we report the screening on 1195 oral-nasopharyngeal swabs collected from students and staff of the Università degli Studi del Sannio (University of Sannio, Benevento, Campania, Italy) and analyzed by an in-house developed multiplex RT-qPCR for SARS-CoV-2 detection through a simple monodimensional sample pooling strategy. Overall, 400 distinct pools were generated and, within 24 h after swab collection, five positive samples were identified. Out of them, four were confirmed by using a commercially available kit suitable for in vitro diagnostic use (IVD). High accuracy, sensitivity and specificity were also determined by comparing our results with a reference IVD assay for all deconvoluted samples. Overall, we conducted 463 analyses instead of 1195, reducing testing resources by more than 60% without lengthening diagnosis time and without significant losses in sensitivity, suggesting that our strategy was successful in recognizing positive cases in a community of asymptomatic individuals with minor requirements of reagents and time when compared to normal testing procedures.


2021 ◽  
Author(s):  
Annet M Nankya ◽  
Luke Nyakarahuka ◽  
Stephen Balinandi ◽  
John Kayiwa ◽  
Julius Lutwama ◽  
...  

Abstract Back ground: Corona Virus Disease 2019 (COVID 19) in Uganda was first reported in a male traveler from Dubai on 21st March, 2020 shortly after WHO had announced the condition as a global pandemic. Timely laboratory diagnosis of COVID -19 for all samples from both symptomatic and asymptomatic patients was observed as key in containing the pandemic and breaking the chain of transmission. However, there was a challenge of limited resources required for testing SARS-COV-2 in low and middle income countries. To mitigate this, a study was conducted to evaluate a sample pooling strategy for COVI-19 using real time PCR. The cost implication and the turn around time of pooled sample testing versus individual sample testing were also compared.Methods: In this study, 1260 randomly selected samples submitted to Uganda Virus Research Institute for analysis were batched in pools of 5, 10, and 15. The pools were then extracted using a Qiagen kit. Both individual and pooled RNA were screened for the SARS-COV-2 E gene using a Berlin kit. Results: Out of 1260 samples tested, 21 pools were positive in pools of 5 samples, 16 were positive in pools of 10 and 14 were positive in pools of 15 samples. The study also revealed that the pooling strategy helps to save a lot on resources, time and expands diagnostic capabilities without affecting the sensitivity of the test in areas with low SARS-COV-2 prevalence.Conclusion: This study demonstrated that the pooling strategy for COVID-19 reduced on the turnaround time and there was a substantial increase in the overall testing capacity with limited resources as compared to individual testing.


Viruses ◽  
2014 ◽  
Vol 6 (8) ◽  
pp. 3311-3333 ◽  
Author(s):  
Nancy Stonos ◽  
Sarah Wootton ◽  
Niel Karrow

2021 ◽  
Author(s):  
Luke Lee ◽  
Fei Liu ◽  
Yuchao Chen ◽  
Gianluca Roma

Abstract The COVID-19 pandemic has become an immense global health crisis. However, the lack of efficient and sensitive on-site testing methods limits early detection for timely isolation and intervention. Here, we present a Quantitative and Ultrasensitive in-situ Immunoassay Technology for SARS-CoV-2 detection in saliva (QUIT SARS-CoV-2). Our nanoporous membrane resonator generates a rapid oscillating flow to purify and concentrate SARS-CoV-2 virus in saliva by 40 folds for in-situ detection of viral antigens based on chemiluminescent immunoassay within 20 min. This method achieved a detection sensitivity below 10 0 copies/mL viral load, comparable to the bench-top PCR equipment. The portable QUIT SARS-CoV-2 system, allowing rapid and accurate on-site viral screen with high-throughput sample pooling strategy, can be performed at the primary care settings and substantially improve the detection and prevention of COVID-19.


2020 ◽  
Author(s):  
Keqin Li

Abstract Testing has been a major factor that limits our response to the COVID-19 pandemic. The method of sample pooling and group test has recently been introduced. However, it is still not clearly known how to determine the appropriate group size. In this paper, we develop an analytical method and a numerical algorithm to determine the optimal group size, which minimizes the total number of tests, maximizes the speedup of the pooling strategy, and minimizes both time and cost of testing. The optimal group size is determined by the fraction of infected people and independent of the size of the population. Furthermore, both the optimal pooling size and the achieved speedup grow exponentially with the reciprocal of the fraction of infected people, a quite impressive and nontrivial result. Our method is effective in supporting faster and cheaper asymptomatic COVID-19 screening. Our research has important social implications and financial impacts. For example, if the percentage of infected people is 0.001, we can achieve speedup of almost 16, which means that months of testing time can be reduced to days, and over 93% of the testing cost can be saved. Such a result has not been available in the known literature, and is a significant progress and great advance in pooling strategy optimization for accelerating asymptomatic COVID-19 screening.


Author(s):  
Yichuan Gan ◽  
Lingyan Du ◽  
Oluwasijibomi Damola Faleti ◽  
Jing Huang ◽  
Gang Xiao ◽  
...  

SummaryBackgroundIdentification of less costly and accurate methods for monitoring novel coronavirus disease 2019 (CoViD-19) transmission has attracted much interest in recent times. Here, we evaluated a pooling method to determine if this could improve screening efficiency and reduce costs while maintaining accuracy in Guangzhou, China.MethodsWe evaluated 8097 throat swap samples collected from individuals who came for a health check-up or fever clinic in The Third Affiliated Hospital, Southern Medical University between March 4, 2020 and April 26, 2020. Samples were screened for CoViD-19 infection using the WHO-approved quantitative reverse transcription PCR (RT-qPCR) primers. The positive samples were classified into two groups (high or low) based on viral load in accordance with the CT value of COVID-19 RT-qPCR results. Each positive RNA samples were mixed with COVID-19 negative RNA or ddH2O to form RNA pools.FindingsSamples with high viral load could be detected in pool negative samples (up to 1/1000 dilution fold). In contrast, the detection of RNA sample from positive patients with low viral load in a pool was difficult and not repeatable.InterpretationOur results show that the COVID-19 viral load significantly influences in pooling efficacy. COVID-19 has distinct viral load profile which depends on the timeline of infection. Thus, application of pooling for infection surveillance may lead to false negatives and hamper infection control efforts.FundingNational Natural Science Foundation of China; Hong Kong Scholars Program, Natural Science Foundation of Guangdong Province; Science and Technology Program of Guangzhou, China.Research in contextEvidence before this studySince it emergence in late 2019, CoViD-19 has dramatically increased the burden healthcare system worldwide. A research letter titled “Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2” which was recently published in JAMA journal proposed that sample pooling could be used for SARS-COV-2 community surveillance. Currently, the need for large-scale testing increases the number of 2019-nCOV nucleic acid analysis required for proper policy-making especially as work and normal school resumes. As far as we know, there are many countries and regions in the world, who are beginning to try this strategy for nucleic acid screening of SARS-CoV-2.Added value of this studyWe carried out a study using pooled samples formed from SARS-COV-2 negative samples and positive samples with high or low viral and assessed detection rate for the positive samples. We found that positive sample with high viral load could be detected in pools in a wide range of dilution folds (ranging from1/2 to 1/50). On the contrary, the sample with low viral load could only be detected in RNA “pools” at very low dilution ratio, and the repeatability was unsatisfactory. Our results show the application of the “pooling” strategy for large-scale community surveillance requires careful consideration and depends on the viral load of the positive samples.Implications of all the available evidenceAlthough the number of newly diagnosed cases has been reducing in some parts of the world, the possibility of a second wave of infection has made quick and efficient data gathering essential for policy-making, isolation and treatment of patients. Fast and efficient nucleic acid detection methods are encouraged, but sample pooling as a strategy of SARS-COV-2 nucleic acid screening increased the false-negative rate, especially those with asymptomatic infections have lower viral load. Therefore, the application of the “pooling” strategy for large-scale community surveillance requires careful consideration by policy makers.


2021 ◽  
Author(s):  
Naif Khalaf Alharbi ◽  
Suliman Alghnam ◽  
Abdullah Algaissi ◽  
Hind Albalawi ◽  
Mohammed W. Alenazi ◽  
...  

AbstractBackgroundEstimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of the COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients.MethodsA total of 11703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimatesResultsOverall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the COVID-19 infection rate. Among HCWs, 7.5% (4.95-10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population.ConclusionOur study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions.


2020 ◽  
Author(s):  
Ton That Thanh ◽  
Nguyen Thi Thanh Nhan ◽  
Huynh Kim Mai ◽  
Nguyen Bao Trieu ◽  
Le Xuan Huy ◽  
...  

We present a sample pooling approach and the results of its application for mass screening of SARS-CoV-2 in >96,000 asymptomatic individuals. Our approach did not compromise the sensitivity of PCR, while increasing the throughput and reducing 77% of the costs. 22/32 asymptomatic cases would have been missed without mass screening.


2021 ◽  
Author(s):  
Matthew M. Hernandez ◽  
Ana S. Gonzalez-Reiche ◽  
Hala Alshammary ◽  
Shelcie Fabre ◽  
Zenab Khan ◽  
...  

ABSTRACTNew York City (NYC) emerged as a coronavirus disease 2019 (COVID-19) epicenter in March 2020, but there is limited information regarding potentially unrecognized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections before the first reported case. We utilized a sample pooling strategy to screen for SARS-CoV-2 RNA in de-identified, respiratory pathogen-negative nasopharyngeal specimens from 3,040 patients across our NYC health system who were evaluated for respiratory symptoms or influenza-like illness during the first 10 weeks of 2020. We obtained complete SARS-CoV-2 genome sequences from samples collected between late February and early March. Additionally, we detected SARS-CoV-2 RNA in pooled specimens collected in the week ending 25 January 2020, indicating that SARS-CoV-2 caused sporadic infections in NYC a full month before the first officially documented case.ONE SENTENCE SUMMARYMolecular surveillance demonstrates that SARS-CoV-2 caused influenza-like illness in NYC before the first reported case.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Matthew M. Hernandez ◽  
Ana S. Gonzalez-Reiche ◽  
Hala Alshammary ◽  
Shelcie Fabre ◽  
Zenab Khan ◽  
...  

AbstractNumerous reports document the spread of SARS-CoV-2, but there is limited information on its introduction before the identification of a local case. This may lead to incorrect assumptions when modeling viral origins and transmission. Here, we utilize a sample pooling strategy to screen for previously undetected SARS-CoV-2 in de-identified, respiratory pathogen-negative nasopharyngeal specimens from 3,040 patients across the Mount Sinai Health System in New York. The patients had been previously evaluated for respiratory symptoms or influenza-like illness during the first 10 weeks of 2020. We identify SARS-CoV-2 RNA from specimens collected as early as 25 January 2020, and complete SARS-CoV-2 genome sequences from multiple pools of samples collected between late February and early March, documenting an increase prior to the later surge. Our results provide evidence of sporadic SARS-CoV-2 infections a full month before both the first officially documented case and emergence of New York as a COVID-19 epicenter in March 2020.


Sign in / Sign up

Export Citation Format

Share Document